ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Nuclear Nonproliferation Policy
The mission of the Nuclear Nonproliferation Policy Division (NNPD) is to promote the peaceful use of nuclear technology while simultaneously preventing the diversion and misuse of nuclear material and technology through appropriate safeguards and security, and promotion of nuclear nonproliferation policies. To achieve this mission, the objectives of the NNPD are to: Promote policy that discourages the proliferation of nuclear technology and material to inappropriate entities. Provide information to ANS members, the technical community at large, opinion leaders, and decision makers to improve their understanding of nuclear nonproliferation issues. Become a recognized technical resource on nuclear nonproliferation, safeguards, and security issues. Serve as the integration and coordination body for nuclear nonproliferation activities for the ANS. Work cooperatively with other ANS divisions to achieve these objective nonproliferation policies.
Meeting Spotlight
Nuclear Energy Conference & Expo (NECX)
September 8–11, 2025
Atlanta, GA|Atlanta Marriott Marquis
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Jun 2025
Jan 2025
Latest Journal Issues
Nuclear Science and Engineering
August 2025
Nuclear Technology
Fusion Science and Technology
July 2025
Latest News
Orano Med expands its Texas Pb-212 R&D center
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.
Hideo Hirayama (Nuclear Regulatory Agency), Kenjiro Kondo (Nuclear Regulatory Agency), Seishiro Sszuki (Nuclear Regulatory Agency), Shimpei Hamamoto (Nuclear Regulatory Agency), Kohei Iwanaga (Nuclear Regulatory Agency)
Proceedings | ICRS 14/RPSD 2022 | Seattle, WA, September 25-29, 2022 | Pages 182-185
